Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients
© 2013 John Wiley & Sons A/S..
BACKGROUND: Cytomegalovirus (CMV) is a major pathogen affecting solid organ transplant (SOT) recipients. Prophylactic strategies have decreased the rate of CMV infection/disease among SOT. However, data on the effect of current prophylactic strategies for simultaneous pancreas-kidney (SPK) or pancreas after kidney (PAK) transplant remain limited. We report our experience of CMV prophylaxis in SPK/PAK recipients.
METHODS: A total of 130 post-SPK/PAK patients were analyzed retrospectively for the rate of CMV and the risk factors associated with the acquisition of CMV. All patients received antiviral prophylaxis. The follow-up period was one yr post-transplant or until death.
RESULTS: The rate of CMV post-SPK/PAK transplant was 24%, 44%, and 8.2% among the whole cohort, the D+/R- and the R+ groups, respectively. Median time of prophylaxis was 49 (0-254) d. In the whole cohort, risk factors for CMV infection/diseases were D+/R- CMV status (odds ratio [OR] = 16.075), preceding non-CMV (infection caused by bacteria or fungi and other viruses) infection (OR = 6.362) and the duration of prophylaxis (OR = 0.984). Among the CMV D+/R- group, non-CMV infection was the only risk factor for CMV disease (OR = 10.7).
CONCLUSIONS: Forty-four per cent (25/57) of the D+/R- recipients developed CMV infection/disease despite CMV prophylaxis. Current CMV prophylaxis failed to prevent CMV infection/disease in this group of patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Clinical transplantation - 27(2013), 4 vom: 15. Juli, Seite 503-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fallatah, Samira M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 11.03.2014 Date Revised 08.08.2013 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ctr.12138 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM228016134 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM228016134 | ||
| 003 | DE-627 | ||
| 005 | 20231224074953.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ctr.12138 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0760.xml |
| 035 | |a (DE-627)NLM228016134 | ||
| 035 | |a (NLM)23731387 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fallatah, Samira M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2014 | ||
| 500 | |a Date Revised 08.08.2013 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2013 John Wiley & Sons A/S. | ||
| 520 | |a BACKGROUND: Cytomegalovirus (CMV) is a major pathogen affecting solid organ transplant (SOT) recipients. Prophylactic strategies have decreased the rate of CMV infection/disease among SOT. However, data on the effect of current prophylactic strategies for simultaneous pancreas-kidney (SPK) or pancreas after kidney (PAK) transplant remain limited. We report our experience of CMV prophylaxis in SPK/PAK recipients | ||
| 520 | |a METHODS: A total of 130 post-SPK/PAK patients were analyzed retrospectively for the rate of CMV and the risk factors associated with the acquisition of CMV. All patients received antiviral prophylaxis. The follow-up period was one yr post-transplant or until death | ||
| 520 | |a RESULTS: The rate of CMV post-SPK/PAK transplant was 24%, 44%, and 8.2% among the whole cohort, the D+/R- and the R+ groups, respectively. Median time of prophylaxis was 49 (0-254) d. In the whole cohort, risk factors for CMV infection/diseases were D+/R- CMV status (odds ratio [OR] = 16.075), preceding non-CMV (infection caused by bacteria or fungi and other viruses) infection (OR = 6.362) and the duration of prophylaxis (OR = 0.984). Among the CMV D+/R- group, non-CMV infection was the only risk factor for CMV disease (OR = 10.7) | ||
| 520 | |a CONCLUSIONS: Forty-four per cent (25/57) of the D+/R- recipients developed CMV infection/disease despite CMV prophylaxis. Current CMV prophylaxis failed to prevent CMV infection/disease in this group of patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cytomegalovirus | |
| 650 | 4 | |a cytomegalovirus prophylaxis | |
| 650 | 4 | |a mismatch | |
| 650 | 4 | |a pancreas after kidney | |
| 650 | 4 | |a simultaneous pancreas- kidney | |
| 650 | 4 | |a simultaneous pancreas- kidney transplantation | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Marquez, Max A |e verfasserin |4 aut | |
| 700 | 1 | |a Bazerbachi, Fateh |e verfasserin |4 aut | |
| 700 | 1 | |a Schiff, Jeffrey R |e verfasserin |4 aut | |
| 700 | 1 | |a Cattral, Mark S |e verfasserin |4 aut | |
| 700 | 1 | |a McGilvray, Ian D |e verfasserin |4 aut | |
| 700 | 1 | |a Norgate, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Selzner, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Rotstein, Coleman |e verfasserin |4 aut | |
| 700 | 1 | |a Husain, Shahid |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical transplantation |d 1987 |g 27(2013), 4 vom: 15. Juli, Seite 503-9 |w (DE-627)NLM07493306X |x 1399-0012 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2013 |g number:4 |g day:15 |g month:07 |g pages:503-9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ctr.12138 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2013 |e 4 |b 15 |c 07 |h 503-9 | ||